Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK's Second-Largest Beauty and Health Retailer
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ:COSM) announces a significant milestone in its UK expansion efforts, by launching its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4%, at Superdrug. Superdrug, the UK’s second-largest beauty and health retailer with over 830 stores and a robust online platform, is well-known for its leadership in health, wellness, and personal care categories. This expansion is a strategic move to enhance Cosmos Health’s market presence and boost C-Scrub’s visibility within a targeted healthcare environment.
C-Scrub is designed to deliver effective skin disinfection, aiming to reduce bacteria and support hygiene by preventing infections. Greg Siokas, CEO of Cosmos Health, shared that entering Superdrug is a testament to the growing momentum the product has seen in the UK market. This partnership allows Cosmos Health to leverage both online and health-focused retail platforms, significantly enhancing brand reach while aligning with the company's aspirations for long-term growth in the region.
Founded in 2009, Cosmos Health is a diversified global healthcare group that produces a wide range of pharmaceutical and nutraceutical products, including C-Scrub and several other well-known brands. The company operates under the stringent European Good Manufacturing Practices and has distribution channels extending throughout Europe, Asia, and North America. In addition to expanding its product portfolio, Cosmos Health is also invested in telehealth through its acquisition of ZipDoctor, showcasing its commitment to innovation and comprehensive healthcare solutions.
With this latest development, Cosmos Health is poised for further growth, backed by its diversified offerings and strategic partnerships in the competitive UK market.
MWN-AI** Analysis
**Market Analysis: Cosmos Health's UK Retail Expansion Through Superdrug**
Cosmos Health Inc. (NASDAQ:COSM) has executed a strategic expansion by launching its antimicrobial product, C-Scrub Wash Chlorhexidine 4%, at Superdrug, the UK's second-largest beauty and health retailer. This entry into Superdrug’s 830-store network, including a substantial online presence, marks a significant step in enhancing Cosmos Health’s visibility and positioning within the UK market.
The retail landscape in the UK is increasingly competitive, particularly in health and personal care sectors. By aligning with Superdrug, well-known for its strong reputation and extensive reach, Cosmos Health can improve its market penetration for C-Scrub. The product's antiseptic properties cater to growing consumer demand for hygiene-focused products, particularly amidst public health trends emphasizing cleanliness and infection prevention.
Investors should view this expansion positively as it signifies a robust approach to building brand recognition and market presence. Greg Siokas, the CEO, emphasized that this partnership will bolster their retail momentum and overall product portfolio's long-term development, suggesting confidence in C-Scrub's acceptance in the consumer healthcare environment.
However, potential investors should remain cautious. Forward-looking statements from Cosmos Health indicate reliance on various external factors, including economic stability and operational efficiency amid geopolitical tensions. As the company navigates its growth—intensified by R&D in innovative therapeutics and entry into telehealth—investors must assess the inherent risks associated with rapid expansion in a fluctuating market.
In summary, while Cosmos Health's venture into Superdrug is a strategically sound decision likely to drive sales and enhance market positioning, investors should perform thorough due diligence, considering both the growth potential and risks involved. Continued monitoring of market trends and company updates will be crucial for informed investment decisions in this evolving landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Superdrug, the UK’s second-largest beauty and health retailer.
Established over 60 years ago, Superdrug is widely recognized for its leadership in health, wellness, and personal care categories and operates more than 830 stores across the UK and the Republic of Ireland, including over 200 in-store pharmacies and a growing number of health clinics, complemented by a strong online e-commerce platform.
C-Scrub Listed on Superdrug.com
C-Scrub is a powerful antiseptic wash offering reliable skin disinfectant properties. It is designed to reduce bacteria and help prevent infection, supporting effective skin hygiene. Expanding into Superdrug’s extensive retail and pharmacy network represents a strategic enhancement of Cosmos Health’s UK market positioning and further increases C-Scrub’s exposure within a focused consumer healthcare environment.
Greg Siokas, CEO of Cosmos Health, stated: “Our entry into Superdrug further reinforces the growing retail momentum for C-Scrub in the UK. Establishing presence across online, broad-based, and health-focused retail platforms significantly strengthens our market positioning. This continued expansion increases brand reach and supports the long-term development of our broader product portfolio across the region.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/28921cdd-6f72-4904-aac4-f42521cc53b9
FAQ**
How does the partnership with Superdrug enhance Cosmos Holdings Inc. COSM's market reach for its C-Scrub product compared to previous distribution strategies in the UK?
What specific benefits does the antimicrobial skin cleanser C-Scrub offer to consumers, and how does this align with Cosmos Holdings Inc. COSM’s broader health strategy?
Given the competitive landscape in the UK health and beauty sector, what measures is Cosmos Holdings Inc. COSM taking to effectively differentiate the C-Scrub brand in Superdrug stores?
Can you elaborate on the anticipated impact of C-Scrub’s availability at Superdrug on Cosmos Holdings Inc. COSM’s overall financial performance and market positioning in 2026?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Holdings Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
4.16% G/L:
$0.3853 Last:
135,725 Volume:
$0.3679 Open:
